©The Author(s) 2016.
World J Gastroenterol. Apr 21, 2016; 22(15): 3892-3906
Published online Apr 21, 2016. doi: 10.3748/wjg.v22.i15.3892
Published online Apr 21, 2016. doi: 10.3748/wjg.v22.i15.3892
Table 1 Potential new avenues for research and therapy in severe alcoholic hepatitis
| Gut microbiota modification |
| Antibiotics (luminal, systemic) |
| Prebiotics and probiotics |
| Fecal microbiota transplantation (FMT) |
| Blockade of LPS and its downstream pathways e.g., PD-1 and TIM-3 inhibition |
| Immune modulation |
| Chemokines e.g., CCL20 inhibition |
| IL-8, IL-17 inhibition |
| Recombinant IL-22, recombinant human IL-10 |
| Osteopontin inhibition |
| TNF-alfa superfamily receptor modulation |
| ADAMTS 13 enhancement |
| Inhibition of complement activation |
| Inhibition of inflammasome activation |
| Increasing steroid sensitivity |
| E.g., Basiliximab, Theophylline |
| Modification of genetic polymorphism of alcohol metabolizing enzymes |
| Epigenetic modification of alcohol induced liver damage |
| Liver regeneration and Early liver transplantation |
| Granulocyte colony stimulating factor (G-CSF) |
| Liver transplantation (DDLT/LDLT) |
| Setting up of alcohol units for post transplant support |
| Others |
| Extracorporeal liver support |
| Granulocytopheresis |
| Anti-oxidants - N-Acetyl Cysteine, S-Adenosyl Methionine |
- Citation: Shasthry SM, Sarin SK. New treatment options for alcoholic hepatitis. World J Gastroenterol 2016; 22(15): 3892-3906
- URL: https://www.wjgnet.com/1007-9327/full/v22/i15/3892.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i15.3892